# Pancreatic Cancer: Resectability and Surgical Approach

## Introduction

Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer death in the United States with a five-year overall survival of approximately 12%. The majority of patients present with locally advanced or metastatic disease, and only 15-20% are candidates for surgical resection at diagnosis. Despite the dismal overall prognosis, R0 surgical resection combined with modern systemic therapy offers the only chance for long-term survival. General surgery residents must understand resectability criteria, operative techniques for pancreatic resection, and the integration of neoadjuvant therapy.

## Anatomy and Pathology

Pancreatic head tumors account for 60-70% of cases and tend to present earlier with obstructive jaundice, involving the uncinate process, common bile duct, and duodenum. Body and tail tumors make up 20-30% of cases and tend to present later with pain, weight loss, and locally advanced disease. The vascular relationships that determine resectability include the superior mesenteric artery, superior mesenteric vein, portal vein, celiac axis, and common hepatic artery. Histologically, ductal adenocarcinoma accounts for more than 85% of pancreatic cancers, with other tumors including acinar cell carcinoma, neuroendocrine tumors, solid pseudopapillary neoplasm, and pancreatoblastoma. Precursor lesions include pancreatic intraepithelial neoplasia (PanIN), intraductal papillary mucinous neoplasm (IPMN), and mucinous cystic neoplasm (MCN). At the molecular level, KRAS mutations are present in more than 90% of PDAC, and other key alterations include TP53, CDKN2A, and SMAD4 loss.

## Clinical Presentation and Diagnosis

Painless obstructive jaundice is the most common presentation for head tumors, accompanied by pruritus, dark urine, and acholic stool. New-onset diabetes mellitus in patients over age 50 may herald PDAC, occurring 2-3 years before diagnosis in up to 25% of cases. Weight loss, anorexia, and pain are common, with epigastric or back pain suggesting retroperitoneal invasion, and pain is more prevalent with body and tail tumors. Courvoisier sign, a palpable nontender gallbladder with jaundice, suggests malignant obstruction. CA 19-9 is elevated in 80% of PDAC and is useful for monitoring treatment response and recurrence, though it is falsely normal in Lewis antigen-negative individuals (5-10%) and falsely elevated with biliary obstruction. Pancreas protocol CT, a triple-phase study with non-contrast, arterial, and portal venous phases using thin 3 mm cuts through the pancreas, is the gold standard for diagnosis, staging, and resectability assessment. Endoscopic ultrasound with fine needle aspiration provides tissue diagnosis and is particularly useful for small tumors not visible on CT and for assessing vascular involvement.

<image>Axial and coronal CT illustrations showing a pancreatic head mass with key vascular relationships labeled including the superior mesenteric artery, superior mesenteric vein, portal vein, celiac axis, and common hepatic artery, with annotation of the criteria for resectable, borderline resectable, and locally advanced categories</image>

## Resectability Classification (NCCN Criteria)

| Category | Arterial Involvement | Venous Involvement | Treatment |
|----------|---------------------|-------------------|-----------|
| Resectable | No contact with SMA, celiac, or CHA | No contact or ≤180° without irregularity | Upfront surgery or neoadjuvant |
| Borderline resectable | SMA/celiac ≤180° without deformity; CHA contact amenable to reconstruction | SMV/PV >180°, contour irregularity, or thrombosis (reconstructible) | Neoadjuvant therapy → surgery |
| Locally advanced | SMA/celiac >180° or aortic involvement | SMV/PV occlusion (non-reconstructible) | Chemotherapy ± reassessment |
| Metastatic | — | — | Systemic therapy; surgery for palliation only |

### Resectable

Resectable tumors have no arterial contact with the SMA, celiac axis, or common hepatic artery, and either no venous contact with the SMV or portal vein or 180 degrees or less of contact without vein contour irregularity. There must be no distant metastases. These patients proceed with either upfront surgery or neoadjuvant therapy.

### Borderline Resectable

Borderline resectable disease involves venous contact with the SMV or portal vein exceeding 180 degrees, contour irregularity, or thrombosis with suitable vessel proximal and distal to the tumor for reconstruction. Arterial involvement includes SMA or celiac axis contact of 180 degrees or less without stenosis or deformity, or common hepatic artery contact without extension to the celiac axis or hepatic artery bifurcation that is amenable to reconstruction. Neoadjuvant therapy is strongly recommended for borderline resectable disease to improve R0 resection rates and to select patients with favorable biology.

### Locally Advanced (Unresectable)

Locally advanced tumors demonstrate SMA or celiac axis contact exceeding 180 degrees, aortic involvement, or SMV/portal vein occlusion without a reconstructible option. These patients are not candidates for curative resection, and treatment consists of systemic chemotherapy with potential for reassessment if a significant response is achieved.

### Metastatic Disease

Metastatic disease includes liver metastases, peritoneal disease, distant lymph node metastases, or positive peritoneal cytology. Systemic therapy is the primary treatment, and surgery is limited to palliation.

## Preoperative Biliary Drainage

Routine preoperative biliary stenting is not recommended for patients proceeding directly to surgery, as the DRAINAGE trial showed increased complications including cholangitis and pancreatitis with routine stenting. Indications for preoperative drainage include bilirubin exceeding 15-20 mg/dL, cholangitis, planned neoadjuvant therapy requiring adequate hepatic function, or significant delay to surgery. Short metal stents are preferred over plastic stents when drainage is required for neoadjuvant therapy because they have fewer occlusion events.

## Surgical Procedures

### Pancreaticoduodenectomy (Whipple Procedure)

Pancreaticoduodenectomy is indicated for tumors of the pancreatic head, uncinate process, distal common bile duct, periampullary region, and duodenum. The structures resected include the pancreatic head and uncinate process, duodenum, distal common bile duct, gallbladder, and distal stomach in the classic Whipple, or with pylorus preservation in the pylorus-preserving pancreaticoduodenectomy (PPPD). Reconstruction requires three anastomoses: pancreaticojejunostomy (or pancreaticogastrostomy), hepaticojejunostomy, and gastrojejunostomy (or duodenojejunostomy in PPPD), all performed on a single jejunal limb. Key operative steps include the Kocher maneuver for duodenal mobilization, assessment of SMV/portal vein involvement at the neck of the pancreas, division of the gastroduodenal artery, and uncinate process dissection along the SMA margin (the retroperitoneal margin). The SMA margin, also called the retroperitoneal or uncinate margin, is the most commonly positive margin, with R1 rates ranging from 15-75% depending on pathologic assessment methods. Vascular resection and reconstruction of the SMV or portal vein is performed when venous involvement is present, using lateral venorrhaphy, primary end-to-end anastomosis, or interposition grafting, and does not worsen survival when R0 is achieved. Arterial resection remains controversial; SMA resection is generally not recommended, though a modified Appleby procedure involving celiac axis resection with hepatic arterial reconstruction may be considered in selected cases.

### Distal Pancreatectomy with Splenectomy

Distal pancreatectomy with splenectomy is indicated for tumors of the pancreatic body and tail. The technique involves en bloc resection of the distal pancreas and spleen with the splenic artery and vein, with transection at the neck of the pancreas using a stapler or suture closure of the pancreatic stump. Radical antegrade modular pancreatosplenectomy (RAMPS) involves posterior dissection anterior to or behind Gerota's fascia to improve retroperitoneal margin clearance and may improve R0 rates and lymph node harvest. Laparoscopic or robotic distal pancreatectomy is oncologically equivalent to the open approach for body and tail tumors and offers faster recovery.

### Total Pancreatectomy

Total pancreatectomy is indicated for a positive pancreatic neck margin on frozen section, multifocal disease such as IPMN with invasive carcinoma, or familial pancreatic cancer with diffuse precursor lesions. It results in obligate insulin-dependent diabetes and exocrine pancreatic insufficiency. Total pancreatectomy with islet autotransplantation (TPIAT) is performed for chronic pancreatitis but not for cancer.

<image>Stepwise surgical illustration of the Whipple procedure showing the specimen including pancreatic head, duodenum, and distal bile duct, followed by the three-anastomosis reconstruction with pancreaticojejunostomy, hepaticojejunostomy, and gastrojejunostomy on a retrocolic jejunal limb</image>

## Neoadjuvant Therapy

The rationale for neoadjuvant therapy includes early treatment of micrometastatic disease, tumor downstaging, improved R0 resection rates, in vivo assessment of tumor biology, and selection of patients who benefit from surgery by identifying those who do not progress during therapy. FOLFIRINOX (5-FU, leucovorin, irinotecan, oxaliplatin) is the preferred regimen for fit patients with good performance status and has been shown to improve survival in both metastatic and resectable settings. Gemcitabine/nab-paclitaxel is an alternative regimen for patients unable to tolerate FOLFIRINOX. The role of neoadjuvant radiation is debated; it may improve local control but has not demonstrated a clear overall survival benefit, and ongoing trials such as ALLIANCE A021501 and PREOPANC-2 are evaluating optimal regimens. Restaging after 2-4 months of neoadjuvant therapy guides the decision to proceed to surgery if there is no disease progression, and stable disease or partial response is sufficient without requiring radiographic downstaging. The CA 19-9 trajectory during neoadjuvant therapy is a powerful prognostic indicator, with rising CA 19-9 during treatment suggesting aggressive biology.

## Postoperative Complications

Postoperative pancreatic fistula is the most feared complication, occurring in 10-25% of cases. It is classified by the ISGPS as biochemical leak (Grade A), Grade B (requiring change in management), and Grade C (organ failure, reoperation, or death). Risk factors include soft pancreatic texture, small duct diameter less than 3 mm, and high BMI. Delayed gastric emptying occurs in 15-40% of patients and is managed conservatively with nasogastric decompression, prokinetics, and nutritional support, though it may be prolonged. Post-pancreatectomy hemorrhage is classified as early (within 24 hours, surgical bleeding) or late (after 24 hours, often from pseudoaneurysm of the GDA stump or hepatic artery), and late hemorrhage with a sentinel bleed requires urgent CT angiography and intervention. Bile leak from the hepaticojejunostomy is managed with percutaneous drainage. Operative mortality is 1-3% at high-volume centers performing more than 20 cases per year, and the volume-outcome relationship is well established.

## Palliation

Biliary obstruction is managed with endoscopic metal stent placement, or surgical hepaticojejunostomy if life expectancy exceeds 6 months or at the time of exploration when unresectability is discovered. Gastric outlet obstruction is treated with endoscopic duodenal stent or surgical gastrojejunostomy. Pain management may require celiac plexus neurolysis, performed endoscopically or under CT guidance, for intractable abdominal or back pain. Prophylactic gastrojejunostomy may be performed at the time of exploratory laparotomy if the tumor is found to be unresectable, as 10-20% of patients develop subsequent duodenal obstruction.

## Key Clinical Pearls

Pancreas protocol CT with thin cuts is mandatory for accurate resectability assessment, and imaging should be reviewed with a radiologist experienced in pancreatic disease. The SMA (retroperitoneal/uncinate) margin is the most commonly positive margin in pancreaticoduodenectomy, and meticulous dissection along the SMA is critical for R0 resection. Neoadjuvant therapy is strongly recommended for borderline resectable disease and increasingly used for clearly resectable PDAC. Pancreaticoduodenectomy should be performed at high-volume centers, as the volume-outcome relationship is among the strongest in surgery. Soft pancreatic texture and small pancreatic duct are the strongest risk factors for postoperative pancreatic fistula, and consideration should be given to duct stenting and appropriate drain management.

## References

1. Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. 2021;19(4):439-457.
2. Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer (PRODIGE 24/CCTG PA.6). *N Engl J Med*. 2018;379(25):2395-2406.
3. Bockhorn M, Uzunoglu FG, Adham M, et al. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). *Surgery*. 2014;155(6):977-988.
4. Bassi C, Marchegiani G, Dervenis C, et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula. *Surgery*. 2017;161(3):584-591.